Search -

Displaying 301 - 320 of 604

Sort: Relevancy | Date

Could NOACs Have a Role for Secondary Prevention After STEMI?

News Daily News

Could NOACs Have a Role for Secondary Prevention After STEMI?

February 08, 2018

Multivessel Disease Patients See Benefits of Long-term Ticagrelor: PEGASUS-TIMI 54 Analysis

News Daily News

Multivessel Disease Patients See Benefits of Long-term Ticagrelor: PEGASUS-TIMI 54 Analysis

Yael L. Maxwell

January 31, 2018

COMPASS Analysis Explores Impact of Low-Dose Rivaroxaban Plus Aspirin on Stroke

News Conference News ISC 2018

COMPASS Analysis Explores Impact of Low-Dose Rivaroxaban Plus Aspirin on Stroke

January 25, 2018

High Rate of Clinical Events at 6 Months for Ischemic CVD Patients

News Daily News

High Rate of Clinical Events at 6 Months for Ischemic CVD Patients

Michael O'Riordan

January 19, 2018

Prolonged DAPT Does Not Increase Mortality, Cancer Risk: More Evidence

News Daily News

Prolonged DAPT Does Not Increase Mortality, Cancer Risk: More Evidence

January 12, 2018

De-escalating DAPT to a Clopidogrel-Based Strategy After PCI for ACS Gets Boost in TOPIC-VASP

News Daily News

De-escalating DAPT to a Clopidogrel-Based Strategy After PCI for ACS Gets Boost in TOPIC-VASP

Yael L. Maxwell

January 04, 2018

Secondary Prevention Improves Survival After STEMI Discharge but Is Widely Underprescribed

News Daily News

Secondary Prevention Improves Survival After STEMI Discharge but Is Widely Underprescribed

December 01, 2017

TCTMD’s Top 10 Most Popular Stories for November 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2017

November 29, 2017

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

News Features

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Michael O'Riordan

November 27, 2017

GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS

News Conference News AHA 2017

GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS

Yael L. Maxwell

November 14, 2017

DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy

News Conference News AHA 2017

DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy

Yael L. Maxwell

November 12, 2017

Circling Back on ORBITA: Sham-Controlled PCI Trial Makes Best of 2017 List

News Conference News AHA 2017

Circling Back on ORBITA: Sham-Controlled PCI Trial Makes Best of 2017 List

Michael O'Riordan

November 12, 2017

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

News Conference News TCT 2017

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

October 30, 2017

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

News Daily News

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

Michael O'Riordan

October 26, 2017

Lesion Complexity and Patient Risk: A Balancing Act for DAPT Duration

News Daily News

Lesion Complexity and Patient Risk: A Balancing Act for DAPT Duration

Yael L. Maxwell

October 23, 2017

Bleeding and Ischemic Events Fluctuate Out to 1 Year Post-STEMI: HORIZONS-AMI

News Daily News

Bleeding and Ischemic Events Fluctuate Out to 1 Year Post-STEMI: HORIZONS-AMI

Yael L. Maxwell

October 03, 2017

Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI

Presentation

Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI

October 03, 2017

Ischemic Heart Disease the Leading Cause of Death Globally

News Daily News

Ischemic Heart Disease the Leading Cause of Death Globally

Michael O'Riordan

September 19, 2017

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

News Features

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

September 15, 2017

Extended Low-Dose Ticagrelor May Prevent Adverse Events Post-MI, Study Finds

News Daily News

Extended Low-Dose Ticagrelor May Prevent Adverse Events Post-MI, Study Finds

Yael L. Maxwell

September 12, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.